ZTSZoetis Inc.

$52B

Q2 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.3B+5.0% YoY

Gross Profit

$807M63.6% margin

Operating Income

$383M30.2% margin

Net Income

$247M19.5% margin

EPS (Diluted)

$0.50

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

$180M

Free Cash Flow

$129M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$7.8B

Total Liabilities

$6.1B

Stockholders' Equity

$1.7B

Cash & Equivalents

$705M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$1.2B	+5.0%
Gross Profit	$807M	$809M	-0.2%
Operating Income	$383M	$356M	+7.6%
Net Income	$247M	$224M	+10.3%

Revenue Segments

Dogs and Cats

$533M42%

Cattle

$382M30%

Swine

$148M12%

Poultry

$122M10%

Horses

$35M3%

Fish

$19M2%

Sheep and Other

$18M1%

ZTS Q2 2017 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena